Diamyd® approved for groundbreaking study in Norway

Diamyd Medical reports today that a prevention study with the Diamyd® diabetes vaccine has been approved by the Norwegian Medicines Agency. As previously communicated on December 9, 2008, the objective of the study is to investigate the disease process before type 1 diabetes onset and if treatment with the Diamyd® diabetes vaccine stops the process.In type 1 diabetes, the insulin-producing capacity is gradually destroyed by the immune system. Already before any symptoms of diabetes appear the disease can be detected through analysis of biomarkers in the blood. If Diamyd® treatment is